The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis

Cited by (181)

Items 101–181 of 181

1. Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases
   Leili Behrooz, Carrie Geisberg Lenneman, Naomi M. Hamburg · 2023 · Current Cardiology Reports
2. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
   Ayako Nagayama, Kenji Ashida, Miki Watanabe, Kanoko Moritaka, Aya Sonezaki, Yoichiro Kitajima, Hirokazu Takahashi, Satoko Yoshinobu, Shimpei Iwata, Junichi Yasuda et al. · 2021 · Frontiers in Endocrinology
3. The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study
   Tingting Wu, Carlos King Ho Wong, Eric Ho Man Tang, Kenneth K. C. Man, Simon Kin‐Hung Wong, Ivan Chi Ho Au, Emily Tsui Yee Tse, Esther W. Chan, Eleanor Grieve, Olívia Wu et al. · 2022 · Surgery for Obesity and Related Diseases
4. Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction
   Tomoya Miyauchi · 2020 · DARU Journal of Pharmaceutical Sciences
5. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data
   Niti Mittal, Vikas Sehray, Rakesh Mittal, Surjit Singh · 2021 · European Journal of Pharmacology
6. The Impact of Sodium-Glucose Co-Transporter-2 Inhibition on Insulin Resistance and Inflammation in Patients with Type 2 Diabetes: A Retrospective Study
   Liana Iordan, Sandra Lazăr, Romulus Zorin Timar, Simona Daniela Popescu, Teodora Sorescu, Oana Albai, Adina Braha, Bogdan Timar, Laura Gaiţă · 2025 · Medicina
7. Sodium-glucose transporter 2 inhibitor for obstructive sleep apnea in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
   Rui‐Feng Yang, Qing Zhao, Jiangfan Guo, Lili Wu, Lingling Qin, Tonghua Liu · 2025 · Sleep Medicine
8. Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials
   Thanakit Suebsaicharoen, Puri Chunekamrai, Teerapat Yingchoncharoen, Amarit Tansawet, Thanaphruet Issarawattana, Pawin Numthavaj, Ammarin Thakkinstian · 2023 · Open Heart
9. Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
   Syed Arman Rabbani, Mohamed El‐Tanani, Ismail Ibrahim Matalka, Imran Rashid Rangraze, Alaa A. A. Aljabali, Mohammad Ahmed Khan, Murtaza M. Tambuwala · 2024 · Expert Review of Endocrinology & Metabolism
10. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials
    Abdulrahman I. Alfayez, Jawaher M. Alfallaj, Mugahid A. Mobark, Abdullah Abdulaziz Alalwan, Osamah M. Alfayez · 2023 · Current Diabetes Reviews
11. Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial
    Marina Vladimirovna Shestakova, Boris B. Kvasnikov, E.E. Erina, Elena Isachenko, Alexander Andreev · 2023 · BMJ Open Diabetes Research & Care
12. Pharmacokinetic characteristics and morphometric effects of sodium-glucose contransporter-2 inhibitors in men and women with type 2 diabetes mellitus (literature review and own results)
    О.В. Prybyla · 2021 · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
13. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
    Ashish Kataria, Christos Argyropoulos · 2022 · Springer eBooks
14. Comparing the Efficacy and Long-Term Outcomes of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Metformin, and Insulin in the Management of Type 2 Diabetes Mellitus
    Farhan Khan, Tanjil Hussain, Taha Zahid Chaudhry, Fnu Payal, Abdullah Shehryar, Abdur Rehman, Afif Ramadhan, Muhammad Tassaduq Hayat, Muath M Dabas, Mustafa Khan · 2024 · Cureus
15. Sodium–Glucose Cotransporter 2 Inhibitors and Lower Risk of Depression in Population with Type 2 Diabetes Mellitus: A Population-Based Active Comparator, New-User Design
    Ming-Jyun Kao, Ying‐Chih Huang, Yu-Chieh Huang, Huiwen Yang, Sheng-Yin To, Chun‐Cheng Liao, Yuan-Liang Wen, Li‐Ting Kao · 2025 · Clinical Epidemiology
16. SGLT2 inhibitor use and renal outcomes in low-risk population with diabetes mellitus and normal or low body mass index
    Yun soo Lee, Goeun Park, Kyungho Lee, Hye Ryoun Jang, Jung Eun Lee, Wooseong Huh, Junseok Jeon · 2025 · BMJ Open Diabetes Research & Care
17. A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
    Tae Seo Sohn, Kyung Ah Han, Yonghyun Kim, Byung‐Wan Lee, Suk Chon, In‐Kyung Jeong, Eun‐Gyoung Hong, Jang Won Son, JaeJin Na, Jae Min Cho et al. · 2024 · Diabetes Obesity and Metabolism
18. Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Transcription Regulation of AgRP and POMC Genes
    Dong Hee Kim, Min Jin Lee, Dasol Kang, Ah Reum Khang, Ji Hyun Bae, Joo Yeon Kim, Su Hyun Kim, Yang Ho Kang, Dongwon Yi · 2024 · Current Issues in Molecular Biology
19. Therapeutic Potential of Cinnamic Acid as an SGLT2 Inhibitor in Mitigating Diabetic Nephropathy in a Rat Model of Type 2 Diabetes
    Setah Naif Alotaibi, Ghedeir Muslem Alshammari, Nawal A. Albadr, Mohammed Abdo Yahya · 2025 · Molecular Nutrition & Food Research
20. Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats
    Aline Bomfim Vieira, Sarah M. Cavanaugh, Bianca Torres Ciambarella, Marcus Vinícius Ribeiro Machado · 2025 · Frontiers in Veterinary Science
21. Promising areas of pharmacotherapy for obesity
    М. A. Druzhilov, Т. Yu. Kuznetsova, Galina A. Chumakova · 2021 · Russian Journal of Cardiology
22. Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin
    Hideaki Jinnouchi, Akira Yoshida, Hiromi Tsuyuno, Kiyoko Iwamoto, Seigo Sugiyama, Kunio Hieshima, Keizo Kajiwara, Noboru Kurinami, Tomoko Suzuki, Katsunori Jinnouchi et al. · 2021 · Diabetes Research and Clinical Practice
23. Fat Mass is Associated with Subclinical Left Ventricular Systolic Dysfunction in Patients with Type 2 Diabetes Mellitus Without Established Cardiovascular Diseases
    Jie Liu, Fan Yang, Qichao Sun, Tianwei Gu, Jing Yao, Ning Zhang, Ran Meng, Dalong Zhu · 2023 · Diabetes Therapy
24. SGLT2 inhibitors: Exploring the effects in humans and horses
    T. Sundra, V. Matthews, P. Harris, D. Rendle · 2024 · Equine Veterinary Education
25. Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the “right drug” and the “right dose” for dogs
    Mutsuki Umezawa, Yoko Fujii, Kensuke Orito, Ryo YOSHIMOTO · 2025 · Journal of Veterinary Medical Science
26. An Insight Into Commercially Available SGLT2 Inhibitors and Their Structure–Activity Relationship Studies
    Asiya Parveen, Shazia Parveen, Nisha Vats, Mohd Shafeeque, Akram Choudhary, Syed Ali Hasnain Zaidi, Mohammad Shahar Yar · 2025 · Archiv der Pharmazie
27. Sweet relief: exploring mechanisms and therapeutic approaches of sodium-glucose cotransporter-2 inhibitors in cardiovascular-kidney metabolic syndrome
    Jiaxin Hua, Qingyuan Wang, Ye Liu, Shengwei Luo, Ao Shi, Zhiwei Yan, Jing Zhang, Wenli Gu, Lihan Zhu, Yuling Zhang et al. · 2026 · Cardiovascular Diabetology
28. Protective Influence of SGLT-2 Inhibitors Against Heart Failure in Type 2 Diabetes Mellitus Through Longitudinal Clinical Database Analysis
    Attila Csaba Nagy, Ágnes Tóth, Natália Bak, Battamir Ulambayar, Amr Sayed Ghanem, Ferenc Sztanek · 2024 · Journal of Clinical Medicine
29. Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study
    Ji‐Hong Park, Kyungdo Han, Hun Jee Choe, Han Na Jang, Hye Mi Kwon, Se‐Eun Park, Eun‐Jung Rhee, Sun Joon Moon, Won‐Young Lee · 2025 · European Heart Journal
30. The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives
    Joaquim Barreto, Alessandra M. Campos‐Staffico, Wilson Nadruz, Thiago Quinaglia, Andrei Carvalho Sposito · 2023 · Frontiers in Clinical Diabetes and Healthcare
31. Discrepancies in Dapagliflozin Response in Terms of Glycemic Control and Body Weight Reduction
    Ji Eun Jun, Kyoung‐Ah Kim, Nan Hee Kim, Kwan Woo Lee, In‐Kyung Jeong, on Behalf of the BEYOND Investigators · 2025 · Endocrinology and Metabolism
32. Sodium-Glucose Cotransporter 2 Inhibitors: Mechanisms of Action and Various Effects
    Kyung-Soo Kim · 2019 · Journal of Korean Diabetes
33. Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hematologic malignancy risk: Insights from Japanese claims data
    Takehiro Kawashiri, NARU YAMAMOTO, Masaki Fujiwara, Tadashi Shimizu, Daisuke Kobayashi, Shunsuke Fujita, Nobuhito Shibata, Takeshi Hirota, Mayako Uchida · 2026 · JNCI Journal of the National Cancer Institute
34. Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial
    Johan T. Bröjer, S. Hanche‐Olsen, Constanze Fintl, Elin Svonni, Ingunn Risnes Hellings, Cecilia Elisabeth Müller, Sanna S. Lindåse · 2026 · Journal of Veterinary Internal Medicine
35. Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM
    Aml Mohamed Nada, Mariam Adel Younan · 2021 · Therapeutic Advances in Endocrinology and Metabolism
36. Elucidating Genetic and Immunological Pathways Mediated by Sodium-Glucose Transporter 2 Inhibitors in Reducing Gout Risk: A Two-Step Mendelian Randomization Study
    Huiqiong Zeng, Junda Lai, Junda Lai, Zhijun Chen, Wei Liu, Ye Zhang · 2025 · Assay and Drug Development Technologies
37. Advances in Cardiovascular Pharmacotherapy. IV. Sodium-Glucose Cotransporter Type 2 Inhibitors, Part 2: Mechanisms for Myocardial Protection, Adverse Effects, and Perioperative Implications
    Paul S. Pagel, Dustin Hang, Julie K. Freed, George J. Crystal · 2025 · Journal of Cardiothoracic and Vascular Anesthesia
38. Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
    Álvaro Contreras, Bruno A. Grassi, Daniela Alfaro‐Sepúlveda, Felipe González, Valeska Ortega · 2019 · Revista médica de Chile
39. Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential
    Lucia Brodosi, Alessandra Musio, Francesca Alessandra Barbanti, Dorina Mita, Giulio Marchesini, Maria Letizia Petroni · 2020 · Hepatoma Research
40. Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report
    Yan Tian, Weiting Hu, Q. Yan, B. Feng · 2023 · Medicina
41. Zaviralci SGLT-2
    Mojca Lunder, Miodrag Janić, Mišo Šabović, Andrej Janež · 2018 · Slovenian Medical Journal
42. Proposed mechanisms of systemic cardiovascular action of gliflosins
    Yakov F. Zverev, A. Ya. Rykunova · 2021 · Reviews on Clinical Pharmacology and Drug Therapy
43. Future Perspectives in the Management of Obesity
    Shilpa Chugh Garcha, Sanjay Kalra · 2025 · Springer eBooks
44. Henagliflozin Increases Serum and Salivary Levels of High-Molecular-Weight Adiponectin in Patients with Type 2 Diabetes in the Community
    Linxin Xu, Chunfan Niu, Yun Liu, Xiaoyu Li, Zhengqian Wang, Jianhong Yin, Mina Li, Qianqian Wu, Ming Liu, Li Sun et al. · 2025 · International Journal of General Medicine
45. Role of SGLT2 inhibitors in the treatment of visceral obesity
    М. A. Druzhilov, Т. Yu. Kuznetsova · 2021 · CARDIOVASCULAR THERAPY AND PREVENTION
46. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience
    Bhupesh Shah, Sanjeev Phatak, Priya Phatak, Harshal B Shah, Isha Phatak, Darshil B. Shah · 2022 · Cureus
47. Association Between Malnutrition and Guideline-Directed Medical Therapy Utilization at Discharge in Hospitalized Patients with Heart Failure
    Xinru Liu, Zhiyan Wang, Shuk Han Chu, Yanfang Wu, Chang Hua, Yangyang Tang, Wenjie Li, Yuling Xiong, Qiang Lv, Chao Jiang et al. · 2025 · Cardiovascular Innovations and Applications
48. Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT-2 inhibitor
    Edyta Cichocka, Janusz Gumprecht · 2019 · Endokrynologia Polska
49. Revisão sobre a eficácia e segurança no uso de inibidores de co-transportadores de sódio-glicose-2 na fisiopatologia da diabetes mellitus tipo II
    Salvador Viana Gomes, João Matheus Caé da Rocha, Francisco Emanoel Alves de Araújo, Bruna Jéssica Dantas de Lucena, Lucas Emmanuel Rocha de Moura Marques, Ismael Vinícius de Oliveira, João Lindemberg Bandeira Lima, Kellyson Lopes da Silva Macêdo · 2020 · Brazilian Journal of Health Review
50. Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
    Ji A Seo · 2018 · Journal of Obesity & Metabolic Syndrome
51. Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
    Dimitrios Patoulias · 2018 · Archives of Medical Science - Atherosclerotic Diseases
52. Les inhibiteurs des SGLT2 : traitement anti diabétiques et/ou de la prévention cardiovasculaire et/ou protection rénale ? Place au débat
    Michel Krempf · 2019 · Archives of Cardiovascular Diseases Supplements
53. Blutdrucksenkende pleiotrope Effekte antidiabetischer Medikamente
    Milen Babic, Markus van der Giet · 2021 · Dialyse aktuell
54. Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
    Muhammad Afzal, Fahad Ahmed Al-Abbasi, Muhammad Shahid Nadeem, Sultan Alshehri, Mohammed M. Ghoneim, Syed Sarim Imam, Waleed Hassan Almalki, Imran Ahmed Kazmi · 2021 · Metabolites
55. Around Australia – Chickens and Campylobacter
    Jillian M. Templeton, J.M. Hewitson, Philip M. Giffard, Patrick Joseph Blackall · 2014
56. Intravital Ca2+ imaging of pancreatic β cell function after bariatric surgery
    Philip Tröster, Per‐Olof Berggren · 2022 · Cell Calcium
57. Peer Review #2 of "Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan (v0.2)"
    2020 · PeerJ
58. Peer Review #1 of "Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan (v0.1)"
    2020 · PeerJ
59. Peer Review #1 of "Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan (v0.2)"
    2020 · PeerJ
60. Peer Review #2 of "Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan (v0.1)"
    2020 · PeerJ
61. Peer Review #1 of "Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan (v0.3)"
    2020 · PeerJ
62. Peer Review #2 of "Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan (v0.3)"
    2020 · PeerJ
63. Therapeutic peptidomimetics in metabolic diseases
    Worood Sirhan, Ron Piran · 2022 · Elsevier eBooks
64. Application and Influence of Dapagliflozin in Patients with Type 2 Diabetes Mellitus
    永萍 王 · 2023 · Medical Diagnosis
65. Type 2 diabetes beyond glycaemic control
    Nikki C. C. Werkman · 2023
66. Saudi Consensus on the Usage of Sodium-Glucose Cotransporter-2 Inhibitors on the Management of Chronic Kidney Diseases
    Abdulrahman Alsheikh, Ahmed H. Al-Jedai, Hajer Almudaiheem, Salwa B. Alaidarous, Ali A. Alshehri, Hussein Elbadawi, Saeed Alghamdi, Faisal Aljehani, Sami A. Alobaidi, Talal A. Altuwaijri et al. · 2023 · International Journal of Clinical Medicine
67. Addressing potential pharmacological adverse reactions of dapagliflozin when taking along with other antidiabetics for the management of type 2 diabetes: A case report
    Mohd Ajmal, Badruddeen Badruddeen, Mukhtar Ahmad, Juber Akhtar, Mohammad Ashraf Alam · 2023 · Annals of Phytomedicine An International Journal
68. A single - center, retrospective observational study comparing the efficacy of empagliflozin and dapagliflozin as add-on therapy in type 2 diabetic patients
    Nguyen Van Vy Hau, Nguyen Van Bang, Nguyen Thi Xuan, Pham Nguyen Tuyen Linh, Nguyen Thi Ngoc Thoi, Vo Thanh Trang, Phan Minh Trung, Le Van Chi, Nguyen Hai Thuy · 2024 · Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế
69. SGLT2 Inhibitors for Primary and Secondary Protection from Cardiovascular and Renal Diseases in Type 2 Diabetes
    Mukesh Nandave · 2024 · Springer eBooks
70. Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT-2) and Dipeptidyl Peptidase 4 (DPP-4) Inhibitor in Weight Reduction in Patients with Type II Diabetes Mellitus
    Qamar Javaid Pansota, Rizwan Rasul Khan, Muhammad Muneeb Majeed · 2024 · Indus journal of bioscience research.
71. Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome
    Chunxiang Xu, Xingyu Qiu, Nan Xu, Gensheng Zhang, Enyin Lai, Liang Zhao · 2025 · Experimental Physiology
72. Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Mellitus: An Umbrella Review of Systematic Reviews
    Muhammed Shabil, Manasa Kasoj, Huma Sulthana, Aftab Ullah, Amogh Verma, Ranjana Sah, Rachana Mehta, Wahby Mohammed Babaresh · 2025 · Diabetes Metabolic Syndrome and Obesity
73. Additional file 1 of Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
    William Hinton, Michael D. Feher, Neil M. Munro, Joy, Mark, de Lusignan, Simon · 2021 · Figshare
74. Additional file 1 of Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial
    Lorenzo Nesti, N. Pugliese, Paolo Sciuto, Trico, Domenico, Angela Dardano, Simona Baldi, Silvia Pinnola, Iacopo Fabiani, Vitantonio Di Bello, Natali, Andrea · 2022 · Figshare
75. Additional file 2 of Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
    William Hinton, Michael D. Feher, Neil M. Munro, Joy, Mark, de Lusignan, Simon · 2021 · Figshare
76. Additional file 2 of Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial
    Lorenzo Nesti, N. Pugliese, Paolo Sciuto, Trico, Domenico, Angela Dardano, Baldi, Simona, Silvia Pinnola, Iacopo Fabiani, Vitantonio Di Bello, Natali, Andrea · 2022 · Figshare
77. Additional file 1 of Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes
    Carmen Hierro‐Bujalance, Carmen Infante‐Garcia, Àngel del Marco, Marta Herrera, María José Carranza-Naval, Suarez, Javier, Pilar Alves-Martínez, Lubian-Lopez, Simon, Mónica Garcı́a-Alloza · 2020 · Figshare
78. Season-adaptive blood pressure management in older adults with CKD: a practical review
    Yoshitaka Furuto, Daiki Yoshino, Iori Ejima, Sayako Ikeda, Akio Namikawa, Dai Sato, Yuko Shibuya · 2026 · Clinical and Experimental Nephrology
79. METFORMIN’S IMPACT ON BODY WEIGHT IN TYPE 2 DIABETES: A NARRATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, AND COMPARATIVE EFFICACY
    Aleksandra Jóźwik-Szymańska, Natalia Kostecka, Laura Mikula, Zuzanna Bogdan-Groszyk, Aleksandra Szredzka, Jan Kucharski, Aleksandra Makulec, Katarzyna Otrębska, Dominika Lewandowska · 2026 · International Journal of Innovative Technologies in Social Science
80. Obesity paradox in heart failure with and without diabetes mellitus: a retrospective cohort study
    Ohchul Kwon, Minjae Yoon, Jin Joo Park · 2026 · Clinical Research in Cardiology
81. Longitudinal Improvement in Waist-to-Height Ratio During SGLT-2 Inhibitor Therapy Within a Structured Multidisciplinary Care Model: A Prospective Real-World Cohort Study
    Süleyman Kılıç, Elif Yıldırım Ayaz, Aziz Kaan Turkoglu, Musa Salmanoğlu, Abdulhamid Arslan, Memnune Sena Ulu · 2026 · Metabolites